Key Highlights

  • Meta Platforms (NASDAQ:META) announced plans on October 26, 2026 to raise up to USD 95 billion for AI infrastructure, with USD 35 billion of immediate equity and a USD 60 billion at-the-market programme in one account of the structure.
  • SpaceX (NASDAQ:SPCX) said it closed USD 40 billion of financing to buy AI chips, with first shipments expected in the first half of 2027, while shares slipped to USD 146.79 against a USD 225.64 record.
  • Surgery Partners (NASDAQ:SGRY) jumped 47.62% after an affiliate of Bon Secours Mercy Health agreed to buy it for USD 23.50 a share in cash, at an enterprise value of about USD 5.7 billion.
  • EQT (NYSE:EQT) agreed to buy Range Resources in an all-stock deal at 0.987 EQT shares for each Range share, creating a company with an enterprise value above USD 50 billion in published market data.

Meta Platforms (NASDAQ:META): Dilution Shock at Meta

Meta Platforms (NASDAQ:META) said on October 26, 2026 that it plans to raise up to USD 95 billion to fund AI infrastructure. The structure reported by one live account is USD 35 billion of immediate underwritten equity plus a USD 60 billion at-the-market programme, though another account says common and preferred shares will both be used. The stock fell 1.88% on the news. Nvidia, AMD and Broadcom were reported to have signalled interest in up to USD 5 billion of the shares. That interest is reported, not confirmed, and the terms may change in the final prospectus or in later filings. The increase in the share count would be the central issue for holders. An underwritten offering is sold at once to banks, which resell the shares to investors, so it raises a large sum quickly but adds shares immediately. An at-the-market programme lets the company sell shares gradually through the exchange at prevailing prices, so it spreads dilution over time but can weigh on the price as sales continue. The scale is also notable because Meta already reported third-quarter results the week before, so this is new capital, not a result. Dilution is not always negative if the new capital earns more than its cost, but that depends on the returns from the AI infrastructure, which are uncertain and may take years to show.

SpaceX (NASDAQ:SPCX): Debt-Funded AI Chips

SpaceX (NASDAQ:SPCX) said on October 26, 2026 that it closed USD 40 billion of financing for AI chips. Musk's statement did not specify the structure, and published accounts conflict: one says corporate bonds, and another says equipment financing. The distinction matters, because bonds are general obligations of the company, while equipment financing is secured against the chips and related assets. First chip shipments are expected in the first half of 2027. The shares slipped to USD 146.79 on the day, below the USD 225.64 record of June 16 and well above the USD 135 debut price of June 12. Musk is the chief executive, so investors read the statement as the company's own. AI chips are expensive, depreciate quickly and take months to deliver, so buyers often borrow to pay for them and repay from the income those chips later generate. A USD 40 billion raise adds interest costs and fixed obligations before any revenue arrives. Separate reports describe Anthropic committing to spend up to USD 120.5 billion with SpaceX through 2029, which, if realised, would give SpaceX a large revenue base to support its own commitments. Bond holders would rank behind secured lenders if the chips are pledged, which affects pricing.

Surgery Partners (NASDAQ:SGRY): Cash Buyout With Rolled Stake

Surgery Partners announced on October 26, 2026 that an affiliate of Bon Secours Mercy Health will buy the company for USD 23.50 a share in cash. The enterprise value of about USD 5.7 billion combines the equity price with the company's net debt. The company release did not state a premium to the prior close or the total equity value, so those must be calculated from market prices after the merger documents are filed. Closing is expected in the first quarter of 2027. The announcement confirmed a take-private report from the previous week, and it replaces the earlier media figure of about USD 20 a share, which proved too low. A merger agreement of this kind normally includes a go-shop or no-shop clause that decides whether the board may seek better offers, and the proxy statement will describe it. In an all-cash acquisition, shareholders receive a fixed price instead of shares in the buyer, so the stock trades near the offer price less a discount for the time and risk until closing. Bain Capital's roughly 39% holding will roll into the new ownership structure, which means the largest holder is staying invested and not cashing out, a signal of continued confidence but also a sign that the other holders' vote matters less.

EQT (NYSE:EQT): All-Stock Gas Merger

The agreement announced on October 26, 2026 is an all-stock merger in which each Range share converts into 0.987 EQT shares. Ownership of the combined company would be about 73% for EQT holders and 27% for Range holders. The combined enterprise value, which adds debt to equity value and subtracts cash, is described as above USD 50 billion. The companies cited about USD 325 million of base annual synergies, with a path to more than USD 600 million, and expect closing in the first quarter of 2027. The release did not state a premium or a per-share price, so any premium figure would be our own arithmetic on market prices. The deal still needs shareholder votes and regulatory clearance before it can complete. In an all-stock deal with a fixed ratio, the value Range holders receive moves with EQT's share price until closing. If EQT shares rise, the deal value rises, and if they fall, it falls. Synergies in natural gas mergers typically come from combining acreage, sharing infrastructure and lowering drilling and administrative costs, and the companies' USD 325 million base figure is a target, not a result.

Where Things Stand

The answer is that the four deals show capital moving in very different forms on October 26, 2026: new equity at Meta Platforms (NASDAQ:META), debt at SpaceX, a cash take-private at Surgery Partners and an all-stock merger at EQT. Dilution, debt load and approvals are the main risks. Meta's final prospectus, SpaceX's financing terms, the Surgery Partners proxy and the EQT merger filings are the next catalysts. Further disclosure from SpaceX (NASDAQ:SPCX) would clarify the picture. Official notices from SpaceX (NASDAQ:SPCX) remain the best guide. Later reporting on EQT (NYSE:EQT) will add detail. Further disclosure from EQT (NYSE:EQT) would clarify the picture.